
    
      Study duration per participant will be approximately 7 months including: 1 day of screening
      and vaccination, a 28-day vaccination period, 1 safety-follow up visit at Day 42, 1 safety
      follow-up/end of study visit at Day 56 and a 6-month safety follow-up call after last vaccine
      administration.
    
  